{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:35:45Z","timestamp":1788287745906,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Azurity Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04777-6","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T09:02:53Z","timestamp":1746954173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic profile of novel reduced-dose Danziten\u2122 (nilotinib tablets) versus Tasigna\u00ae (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis"],"prefix":"10.1007","volume":"95","author":[{"given":"Michael","family":"Mauro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paras","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bellanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Douer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"key":"4777_CR1","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H (2022) Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol 97:1236\u20131256. https:\/\/doi.org\/10.1002\/ajh.26642","journal-title":"Am J Hematol"},{"key":"4777_CR2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2217\/fon-2018-0468","volume":"15","author":"T Sacha","year":"2019","unstructured":"Sacha T, Saglio G (2019) Nilotinib in the treatment of chronic myeloid leukemia. Future Oncol 15:953\u2013965. https:\/\/doi.org\/10.2217\/fon-2018-0468","journal-title":"Future Oncol"},{"key":"4777_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129\u2013141. https:\/\/doi.org\/10.1016\/j.ccr.2005.01.007","journal-title":"Cancer Cell"},{"key":"4777_CR4","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500\u20134505. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0259","journal-title":"Cancer Res"},{"key":"4777_CR5","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1080\/0284186X.2023.2263152","volume":"62","author":"SH Cha","year":"2023","unstructured":"Cha SH, Kim K, Song YK (2023) Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis. Acta Oncol 62:1767\u20131774. https:\/\/doi.org\/10.1080\/0284186X.2023.2263152","journal-title":"Acta Oncol"},{"key":"4777_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/BTT.S67844","volume":"10","author":"J Emole","year":"2016","unstructured":"Emole J, Talabi T, Pinilla-Ibarz J (2016) Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib. Biologics 10:23\u201331. https:\/\/doi.org\/10.2147\/BTT.S67844","journal-title":"Biologics"},{"key":"4777_CR7","unstructured":"Tasigna prescribing information (2024) https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/tasigna.pdf. Accessed 17 September 2024"},{"key":"4777_CR8","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","volume":"30","author":"DL Deremer","year":"2008","unstructured":"Deremer DL, Ustun C, Natarajan K (2008) Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 30:1956\u20131975. https:\/\/doi.org\/10.1016\/j.clinthera.2008.11.014","journal-title":"Clin Ther"},{"key":"4777_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1517\/14740338.2011.532486","volume":"10","author":"TD Kim","year":"2011","unstructured":"Kim TD, le Coutre P (2011) The expanding role of nilotinib in chronic myeloid leukemia. Expert Opin Drug Saf 10:97\u2013107. https:\/\/doi.org\/10.1517\/14740338.2011.532486","journal-title":"Expert Opin Drug Saf"},{"key":"4777_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.208","volume":"87","author":"C Tanaka","year":"2010","unstructured":"Tanaka C, Yin OQ, Sethuraman V et al (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87:197\u2013203. https:\/\/doi.org\/10.1038\/clpt.2009.208","journal-title":"Clin Pharmacol Ther"},{"key":"4777_CR11","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044\u20131054. https:\/\/doi.org\/10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"4777_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128761","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Saglio G, Larson RA (2019) Long-term outcomes in patients with chronic myeloid leukemia in chronic phase receiving frontline nilotinib versus imatinib: enestnd 10-year analysis. Blood. https:\/\/doi.org\/10.1182\/blood-2019-128761","journal-title":"Blood"},{"key":"4777_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA et al (2021) Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 35:440\u2013453. https:\/\/doi.org\/10.1038\/s41375-020-01111-2","journal-title":"Leukemia"},{"key":"4777_CR14","doi-asserted-by":"publisher","first-page":"966182","DOI":"10.3389\/fcvm.2022.966182","volume":"9","author":"S Li","year":"2022","unstructured":"Li S, He J, Zhang X et al (2022) Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: a systematic review, meta-analysis and integrative bioinformatics analysis. Front Cardiovasc Med 9:966182. https:\/\/doi.org\/10.3389\/fcvm.2022.966182","journal-title":"Front Cardiovasc Med"},{"key":"4777_CR15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","volume":"69","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Yin OQ, Sallas WM et al (2013) Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol 69:813\u2013823. https:\/\/doi.org\/10.1007\/s00228-012-1385-4","journal-title":"Eur J Clin Pharmacol"},{"key":"4777_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","volume":"68","author":"RA Larson","year":"2012","unstructured":"Larson RA, Yin OQ, Hochhaus A et al (2012) Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol 68:723\u2013733. https:\/\/doi.org\/10.1007\/s00228-011-1200-7","journal-title":"Eur J Clin Pharmacol"},{"key":"4777_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/JU.0000000000003081","volume":"209","author":"CS Higano","year":"2023","unstructured":"Higano CS, Hafron J (2023) Adherence with oral anticancer therapies: clinical trial vs real-world experiences with a focus on prostate cancer. J Urol 209:485\u2013493. https:\/\/doi.org\/10.1097\/JU.0000000000003081","journal-title":"J Urol"},{"key":"4777_CR18","unstructured":"United States Food and Drug Administration (2021) Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug. Accessed 7 September 2024"},{"key":"4777_CR19","unstructured":"National Comprehensive Cancer Network (2024) Chronic Myeloid Leukemia Version 2.2024 \u2014 December 5, 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf. Accessed 21 September 2024"},{"key":"4777_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14330","author":"A Shacham-Abulafia","year":"2024","unstructured":"Shacham-Abulafia A, Volcheck Y, Ellis M et al (2024) Asciminib in Advanced-line treatment of chronic myeloid leukemia. Eur J Haematol. https:\/\/doi.org\/10.1111\/ejh.14330","journal-title":"Eur J Haematol"},{"key":"4777_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/ejh.13418","volume":"105","author":"CCLM Boons","year":"2020","unstructured":"Boons CCLM, den Hartog YM, Janssen JJWM et al (2020) Food-effect study of nilotinib in chronic myeloid leukemia (NiFo study): enabling dose reduction and relief of treatment burden. Eur J Haematol 105:148\u2013155. https:\/\/doi.org\/10.1111\/ejh.13418","journal-title":"Eur J Haematol"},{"key":"4777_CR22","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1177\/0091270010384116","volume":"51","author":"OQ Yin","year":"2011","unstructured":"Yin OQ, Rudoltz M, Galetic I et al (2011) Effects of yogurt and applesauce on the oral bioavailability of nilotinib in healthy volunteers. J Clin Pharmacol 51:1580\u20131586. https:\/\/doi.org\/10.1177\/0091270010384116","journal-title":"J Clin Pharmacol"},{"key":"4777_CR23","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s00228-020-02910-3","volume":"76","author":"CCLM Boons","year":"2020","unstructured":"Boons CCLM, Timmers L, Janssen JJWM et al (2020) Response and adherence to nilotinib in daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. Eur J Clin Pharmacol 76:1213\u20131226. https:\/\/doi.org\/10.1007\/s00228-020-02910-3","journal-title":"Eur J Clin Pharmacol"},{"key":"4777_CR24","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1186\/1477-7525-11-167","volume":"118","author":"S Gupta","year":"2011","unstructured":"Gupta S, Goren A, Victor TW et al (2011) Associations between treatment restrictions, patient-reported treatment burden and adherence to tyrosine-kinase inhibitor therapy among chronic myeloid leukemia patients in the United States and Europe. Blood 118:2077. https:\/\/doi.org\/10.1186\/1477-7525-11-167","journal-title":"Blood"},{"issue":"Suppl 15","key":"4777_CR25","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1200\/jco.2012.30.15_suppl.6042","volume":"15","author":"B Muluneh","year":"2012","unstructured":"Muluneh B, Alexander M, Deal A et al (2012) Prospective evaluation of perceived barriers to medication adherence by patients on oral antineoplastics. J Clin Oncol 15(Suppl 15):6042. https:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.6042","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04777-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T09:05:56Z","timestamp":1747213556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04777-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,11]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4777"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04777-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5462775\/v1","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,11]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.M. is a consultant to Bristol Myers Squibb, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc. M.M. has received research funding from Bristol Myers Squibb, Novartis, Sun Pharma Advanced Research Company (SPARC). M.M. has received honoraria from Novartis. J.R. has received honoraria from ThermoFisher. P.J. and D.S. are employees of Azurity Pharmaceuticals, Inc. F.B. is employee of Certara. D.D. serves on Speakers\u2019 Bureau with Amgen and Servier. D.D. is a consultant to Servier and Jazz Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"56"}}